Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Published:2018-04-13 Issue:1 Volume:7 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Mita Akiko,Abumiya Maiko,Miura Masatomo,Niioka Takenori,Takahashi Saori,Yoshioka Tomoko,Kameoka Yoshihiro,Takahashi Naoto^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s40164-018-0101-1.pdf

Reference17 articles.

1. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–76.

2. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403–12.

3. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–18.

4. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.

5. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity;Toxicology Letters;2024-10

2. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial);International Journal of Hematology;2024-08-13

3. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25

4. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

5. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05